CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

The trial will be a collaborative effort between the company, the Norwegian Cancer Society, and Cancer Research UK.

Researchers at the University of California San Diego School of Medicine have identified a potential new treatment, an ...

New research reveals that MRI distance measures may more accurately predict cognitive decline during the preclinical phase of ...

In 2025, newly-designed clinical trials for people with cancer are providing new options and hope for patients and their ...

The first clinical trial to test whether adults allergic to peanuts can be desensitized has shown great success with two ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex Pharmaceuticals. | Mosaic ...

Mosaic Therapeutics, Ltd ('Mosaic') a targeted oncology therapeutics company dedicated to resolving cancer's complexity with new combination therapies for patients, today announces the in-licensing of ...

Health and Human Services Secretary Robert. F. Kennedy Jr. unveiled a plan on Tuesday to start phasing out eight synthetic ...

Controversies in the Treatment of Ischemia-Reperfusion Injury, ” will focus on past and current strategies for reducing the myocardial damage caused by IRI following percutaneous coronary intervention ...

NDV-01 is a novel, investigational, sustained-release gemcitabine/docetaxel formulation, designed as a ready-for-use intravesical therapy for the treatment of NMIBC. The U.S. prevalence of NMIBC is ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...